Multiple Sclerosis in a Patient with Intermediate Uveitis and Juvenile Idiopathic Arthritis Treated with Adalimumab: A Case Report

William Rojas-Carabali; Laura Boada-Robayo; Daniela Chacón-Zambrano; Eveling Criollo Porras; Valentina Kerguelén Dumar; Alejandra de-la-Torre

doi:10.1080/09273948.2022.2113800

Multiple Sclerosis in a Patient with Intermediate Uveitis and Juvenile Idiopathic Arthritis Treated with Adalimumab: A Case Report

Título traducido de la contribución: Esclerosis múltiple en un paciente con uveítis intermedia y artritis idiopática juvenil tratado con adalimumab: reporte de un caso

William Rojas-Carabali
, Laura Boada-Robayo
, Daniela Chacón-Zambrano
, Eveling Criollo Porras
, Valentina Kerguelén Dumar
, Alejandra de-la-Torre

Producción científica: Contribución a revista › Artículo de Investigación › revisión exhaustiva

5 Citas (Scopus)

Resumen

Objetivo: Reportar un caso de desarrollo de esclerosis múltiple (EM) en un paciente con Artritis Idiopática Juvenil (AIJ) y uveítis intermedia (UI) bilateral tratado con Adalimumab.
Reporte de un caso: Mujer colombiana de 21 años con diagnóstico de AIJ y UI refractaria bilateral tratada con metotrexato y adalimumab con difícil control de la enfermedad y múltiples complicaciones oculares. Ocho años después de iniciar Adalimumab, el paciente presentó parestesia en miembro superior izquierdo. Los hallazgos radiológicos en la resonancia magnética del cerebro y la columna cervical confirmaron el diagnóstico de EM.
Conclusiones: Presentamos el primer caso de desarrollo de EM en un paciente con AIJ tratado con Adalimumab y el tercero en un paciente con uveítis no infecciosa tratado con anti-TNFα. Aún no se sabe si la EM es secundaria a la terapia anti-TNFα o está relacionada con un fenómeno de poliautoinmunidad.

Título traducido de la contribución	Esclerosis múltiple en un paciente con uveítis intermedia y artritis idiopática juvenil tratado con adalimumab: reporte de un caso
Idioma original	Inglés estadounidense
Páginas (desde-hasta)	1-4
Número de páginas	4
Publicación	Ocular Immunology and Inflammation
DOI	https://doi.org/10.1080/09273948.2022.2113800
Estado	Publicada - sep. 23 2022

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

ODS 3: Salud y bienestar

Áreas temáticas de ASJC Scopus

Inmulogía y alergología
Oftalmología

Acceder al documento

10.1080/09273948.2022.2113800

Otros archivos y enlaces

Citar esto

@article{a68940aeceba4732be80c2453a7db5a3,

title = "Multiple Sclerosis in a Patient with Intermediate Uveitis and Juvenile Idiopathic Arthritis Treated with Adalimumab: A Case Report",

abstract = "Purpose: To report a case of multiple sclerosis (MS) development in a patient with Juvenile Idiopathic Arthritis (JIA) and bilateral intermediate uveitis (IU) treated with Adalimumab. Case report: A 21-year-old Colombian woman diagnosed with JIA and bilateral refractory IU treated with methotrexate and Adalimumab with difficult control of the disease and multiple ocular complications. Eight years after starting Adalimumab, the patient presented paresthesia in the left upper limb. Radiologic findings in the brain and cervical spine MRI confirmed the diagnosis of MS. Conclusions: We reported the first case of MS development in a patient with JIA treated with Adalimumab and the third in a patient with noninfectious uveitis treated with anti-TNFα. It remains uncertain whether MS is secondary to anti-TNFα therapy or is linked to a polyautoimmunity phenomenon.",

author = "William Rojas-Carabali and Laura Boada-Robayo and Daniela Chac{\'o}n-Zambrano and \{Criollo Porras\}, Eveling and \{Kerguel{\'e}n Dumar\}, Valentina and Alejandra de-la-Torre",

note = "Publisher Copyright: {\textcopyright} 2022 Taylor \& Francis Group, LLC.",

year = "2022",

month = sep,

day = "23",

doi = "10.1080/09273948.2022.2113800",

language = "English (US)",

pages = "1--4",

journal = "Ocular Immunology and Inflammation",

issn = "0927-3948",

publisher = "Taylor and Francis Ltd.",

}

Multiple Sclerosis in a Patient with Intermediate Uveitis and Juvenile Idiopathic Arthritis Treated with Adalimumab: A Case Report. / Rojas-Carabali, William; Boada-Robayo, Laura; Chacón-Zambrano, Daniela et al.
En: Ocular Immunology and Inflammation, 23.09.2022, p. 1-4.

Producción científica: Contribución a revista › Artículo de Investigación › revisión exhaustiva

TY - JOUR

T1 - Multiple Sclerosis in a Patient with Intermediate Uveitis and Juvenile Idiopathic Arthritis Treated with Adalimumab

T2 - A Case Report

AU - Rojas-Carabali, William

AU - Boada-Robayo, Laura

AU - Chacón-Zambrano, Daniela

AU - Criollo Porras, Eveling

AU - Kerguelén Dumar, Valentina

AU - de-la-Torre, Alejandra

PY - 2022/9/23

Y1 - 2022/9/23

N2 - Purpose: To report a case of multiple sclerosis (MS) development in a patient with Juvenile Idiopathic Arthritis (JIA) and bilateral intermediate uveitis (IU) treated with Adalimumab. Case report: A 21-year-old Colombian woman diagnosed with JIA and bilateral refractory IU treated with methotrexate and Adalimumab with difficult control of the disease and multiple ocular complications. Eight years after starting Adalimumab, the patient presented paresthesia in the left upper limb. Radiologic findings in the brain and cervical spine MRI confirmed the diagnosis of MS. Conclusions: We reported the first case of MS development in a patient with JIA treated with Adalimumab and the third in a patient with noninfectious uveitis treated with anti-TNFα. It remains uncertain whether MS is secondary to anti-TNFα therapy or is linked to a polyautoimmunity phenomenon.

AB - Purpose: To report a case of multiple sclerosis (MS) development in a patient with Juvenile Idiopathic Arthritis (JIA) and bilateral intermediate uveitis (IU) treated with Adalimumab. Case report: A 21-year-old Colombian woman diagnosed with JIA and bilateral refractory IU treated with methotrexate and Adalimumab with difficult control of the disease and multiple ocular complications. Eight years after starting Adalimumab, the patient presented paresthesia in the left upper limb. Radiologic findings in the brain and cervical spine MRI confirmed the diagnosis of MS. Conclusions: We reported the first case of MS development in a patient with JIA treated with Adalimumab and the third in a patient with noninfectious uveitis treated with anti-TNFα. It remains uncertain whether MS is secondary to anti-TNFα therapy or is linked to a polyautoimmunity phenomenon.

UR - https://www.scopus.com/pages/publications/85139155136

UR - https://www.scopus.com/pages/publications/85139155136#tab=citedBy

UR - https://www.mendeley.com/catalogue/e7f664a9-948d-38d7-bcad-924e61b34cc0/

U2 - 10.1080/09273948.2022.2113800

DO - 10.1080/09273948.2022.2113800

M3 - Research Article

C2 - 36150118

AN - SCOPUS:85139155136

SN - 0927-3948

SP - 1

EP - 4

JO - Ocular Immunology and Inflammation

JF - Ocular Immunology and Inflammation

ER -

Multiple Sclerosis in a Patient with Intermediate Uveitis and Juvenile Idiopathic Arthritis Treated with Adalimumab: A Case Report

Resumen

ODS de las Naciones Unidas

Áreas temáticas de ASJC Scopus

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto